Kidney Specialists of MN, PA, is a group of nephrologists and critical care physicians with offices serving the Twin Cities (Minneapolis/St. Paul) metropolitan area. KSM established Twin Cities Clinical Research in 1982 with a commitment to conducting high quality, professional clinical studies for the pharmaceutical industry.
Twin Cities Clinical Research has conducted Phase II, III, and IV clinical trials in the following areas: hypertension, hyperlipidemia, dyslipidimia, obesity, renal insufficiency, diabetes, pre-diabetes, osteoporosis, osteopenia, hormone replacement therapy, vaccines, osteoarthritis, heartburn, vaginal dryness, orthostatic hypotension, hemodialysis, peritoneal dialysis, transplantation, kidney stones, erectile dysfunction, gout, and irritable bowel syndrome.
We have developed a reputation for accuracy, thoroughness, timeliness, and reliability. Our customers include: Abbott Labs, Alexion, Amgen, Amylin Pharmaceuticals, AstraZeneca, Aventis, Bayer pharmaceuticals, Bertek, Boehringer-Ingelheim, Boston Biostatics, Bristol-Myers Squibb, Centocor, Chugai-Upjohn, Ciba-Geigy, Clinical Research International, Clinical Research Management, ClinTrials, Covalent, Covance, Dynavax, Eli Lilly & Co., Fibrogen, Forest Labs., Hoechst-Roussel, Genetech, Genzyme, GlaxoWellcome, GlaxoSmithKline, Hoffman-LaRoche, ICON, Insmed, IOMAI, King, KOS, Luitpold, Marion Laboratories, Medpace, Merck Sharp & Dohme, Miles, MTRA, Myogen, NicOx, Novartis, Omnicare, Ortho-Biotech, Paragon Biomedical, Paraxel, Parke-Davis Pharmaceutical, Pfizer Inc., Pharmaceutical Research Associates (PRA), PPD, Pharmacia, PLIVA, Premier Research, Quintiles, Roberts Pharmaceuticals, Roche, Sanofi, Searle, Shire, SmithKline Beecham, Sankyo, Scios-Nova, Synergen, TAP Pharmaceuticals, Wyeth-Ayerst Pharmaceuticals, and Upjohn Company.
N. Martin Lunde, MD, Medical Director
Internal Medicine/Nephrology
Daniel K. Ries, MD, Sub-Investigator
Internal Medicine/Nephrology
George C. Canas, MD, Sub-investigator
Internal Medicine/Nephrology
Jane McGinley RN, CCRC
Program Director,
Study Coordinator
We also have a dedicated Regulatory Coordinator, Contract & Grant Specialist, 4 Clinical Research Coordinators, 2 Coordinator Assistants, Registered Dietitian, and 2 Recruitment Specialists.
Twin Cities Clinical Research is able to recruit qualified and reliable study participants from our extensive database, private practice, and through our community. We use radio, newspaper, direct mailing, and target publications for advertising.
Cardiology/Vascular Diseases
Endocrinology
Nephrology/Urology
Twin Cities Clinical Research has one primary investigative site where we conduct our clinical studies; we also have specialty affiliations in the Twin Cities area. Radiological and ultrasound services are provided by a nearby hospital. Dexa Scans are available. We also have experience with holter monitoring, ambulatory blood pressure monitoring, remote data entry, and many other study-specific procedures. Our site provides locked storage for security of supplies and information. Additionally, because our site is located near major medical centers, we are able to work closely with certified laboratory facilities to provide quick turnaround and accurate results.
The Minneapolis/St.Paul International Airport provides easy access to the Twin Cities and our investigative site. We are located at the I-694 and Shingle Creek Parkway in Brooklyn Center, MN. Free parking for our visitors. Restaurants, sports, theatres, and shopping are nearby, including the Mall of America (near the airport). Come and enjoy our beautiful metropolitan area.
Jane McGinley, RN, CCRC
Program Director
Twin Cities Clinical Research
6200 Shingle Creek Parkway, Suite 300
Brooklyn Center, MN 55430
USA
763-746-9010
763-746-9022 (fax)
TCCR@ISD.net
- Are you living with moderate to severe hot flashes?
- Concerned about your Cholesterol?
- Do you have Kidney Disease?
- Do you suffer from GOUT ATTACKS?
- Hepatitis B is a viral infection of the liver that can become chronic and is contagious. This virus becomes a major threat to many people, in particular to people with progressive kidney disease.
- If you are Type 2 diabetic and currently taking ACTOS (30 or 45 mg), you may be eligible to be in a clinical research study offering new treatment options